<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00061113</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-13176-1</org_study_id>
    <secondary_id>R01-13176-1</secondary_id>
    <nct_id>NCT00061113</nct_id>
  </id_info>
  <brief_title>Substance Dependent Teens - Impact of Treating Depression Study 1 - 1</brief_title>
  <official_title>Substance Dependent Teens - Impact of Treating Depression Study 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the impact of treating depression on substance
      dependent teens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary study aim is to determine whether fluoxetine + CBT is a more effective treatment
      than placebo + CBT for substance outcomes, depression, and behavior problems. The current
      community standard of care often withholds pharmacotherapy for depression in substance
      abusing adolescents, since it is often assumed that their depressions may remit with SUD
      treatment alone. However, this is an untested hypothesis in adolescents and one that we
      propose to test in the current study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine whether fluoxetine + CBT is a more effective treatment than placebo + CBT for substance outcomes, depression, and behavior problems.</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine if the treatment of depression with fluoxetine + CBT, in depressed adolescents with SUD and CD will be more effective than placebo + CBT in reducing substance use and improving conduct symptoms.</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Alcohol-Related Disorders</condition>
  <condition>Marijuana Abuse</condition>
  <condition>Substance-Related Disorders</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>fluoxetine + CBT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo + CBT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine + outpatient cognitive behavioral therapy</intervention_name>
    <description>single fixed morning dose 20 mg X 15 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Prozac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluoxetine</intervention_name>
    <description>20mg, QD x 16 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>prozac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo + CBT</intervention_name>
    <description>single fixed morning dose X 16 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have DSM IV non bipolar Major Depressive disorder (by clinical interview), DSM IV
             Conduct Disorder, and Non-Tobacco Substance Disorder.

        Exclusion Criteria:

          -  History of or current psychosis, history of psychotic depression, bipolar disorder I
             or II, family history of first degree relative with bipolar I, lifetime history of
             non-substance induced Mania/Hypomania

          -  Unstable chronic or serious medical illness

          -  Currently pregnant

          -  Take psychotrophic medication, past 2 months: medication or treatment for depression,
             clinically significant laboratory abnormality
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paula Riggs, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1611 South Federal Blvd.</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Deas D, Riggs P, Langenbucher J, Goldman M, Brown S. Adolescents are not adults: developmental considerations in alcohol users. Alcohol Clin Exp Res. 2000 Feb;24(2):232-7.</citation>
    <PMID>10698377</PMID>
  </reference>
  <reference>
    <citation>Davies RD, Gabbert SL, Riggs PD. Anxiety Disorders in Neurologic Illness. Curr Treat Options Neurol. 2001 Jul;3(4):333-346.</citation>
    <PMID>11389804</PMID>
  </reference>
  <reference>
    <citation>Riggs PD, Davies RD. A clinical approach to integrating treatment for adolescent depression and substance abuse. J Am Acad Child Adolesc Psychiatry. 2002 Oct;41(10):1253-5.</citation>
    <PMID>12364848</PMID>
  </reference>
  <reference>
    <citation>Riggs PD. Treating adolescents for substance abuse and comorbid psychiatric disorders. Sci Pract Perspect. 2003 Aug;2(1):18-29.</citation>
    <PMID>18552718</PMID>
  </reference>
  <reference>
    <citation>Laudenslager, M.L., Neu, M., Riggs, P., Goldstein, M., &amp; Lohman, M. Refinements in a novel technique for collecting saliva for steroid hormone determinations. Brain Behavior, and Immunity, 17 (3), 186, 2003.</citation>
  </reference>
  <reference>
    <citation>Riggs PD, Hall SK, Mikulich-Gilbertson SK, Lohman M, Kayser A. A randomized controlled trial of pemoline for attention-deficit/hyperactivity disorder in substance-abusing adolescents. J Am Acad Child Adolesc Psychiatry. 2004 Apr;43(4):420-9.</citation>
    <PMID>15187802</PMID>
  </reference>
  <reference>
    <citation>Davies RD, Thurstone C, Woyewodzic K. Substance Use Disorders and Neurologic Illness. Curr Treat Options Neurol. 2004 Sep;6(5):421-432.</citation>
    <PMID>15279762</PMID>
  </reference>
  <reference>
    <citation>Libby AM, Orton HD, Stover SK, Riggs PD. What came first, major depression or substance use disorder? Clinical characteristics and substance use comparing teens in a treatment cohort. Addict Behav. 2005 Oct;30(9):1649-62. Epub 2005 Aug 11.</citation>
    <PMID>16098679</PMID>
  </reference>
  <reference>
    <citation>Libby AM, Riggs PD. Integrated substance use and mental health treatment for adolescents: aligning organizational and financial incentives. J Child Adolesc Psychopharmacol. 2005 Oct;15(5):826-34. Review.</citation>
    <PMID>16262598</PMID>
  </reference>
  <reference>
    <citation>Libby, A.M. and Riggs, P.D. The Economics of Integrated Care for Adolescents with Mental and Substance Use Disorders. Journal of Child and Adolescent Psychopharmacology, 15(5): October 2005</citation>
  </reference>
  <reference>
    <citation>Drell MJ, Josephson A, Pleak R, Riggs P, Rosenfeld A. Clinical problem solving: the case of John, Part II: excerpts from Sessions 2-7. J Am Acad Child Adolesc Psychiatry. 2006 Oct;45(10):1243-51.</citation>
    <PMID>17003670</PMID>
  </reference>
  <reference>
    <citation>Thurstone C, Riggs PD, Klein C, Mikulich-Gilbertson SK. A one-session human immunodeficiency virus risk-reduction intervention in adolescents with psychiatric and substance use disorders. J Am Acad Child Adolesc Psychiatry. 2007 Sep;46(9):1179-86.</citation>
    <PMID>17712241</PMID>
  </reference>
  <reference>
    <citation>Riggs, P.D. Understanding the Abuse of Commonly Prescribed Medications and Approaches to Prevention. Current Medical Research and Opinion, 2007</citation>
  </reference>
  <reference>
    <citation>Riggs PD, Mikulich-Gilbertson SK, Davies RD, Lohman M, Klein C, Stover SK. A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders. Arch Pediatr Adolesc Med. 2007 Nov;161(11):1026-34.</citation>
    <PMID>17984403</PMID>
  </reference>
  <reference>
    <citation>Riggs PD, Thompson LL, Tapert SF, Frascella J, Mikulich-Gilbertson S, Dalwani M, Laudenslager M, Lohman M. Advances in neurobiological research related to interventions in adolescents with substance use disorders: research to practice. Drug Alcohol Depend. 2007 Dec 1;91(2-3):306-11.</citation>
    <PMID>18038460</PMID>
  </reference>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2003</study_first_submitted>
  <study_first_submitted_qc>May 21, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2003</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <name_title>Paula Riggs, M.D.</name_title>
    <organization>University of Colorado Denver</organization>
  </responsible_party>
  <keyword>alcohol dependence</keyword>
  <keyword>marijuana dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Marijuana Abuse</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Alcohol-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluoxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

